Company news

Frontier Biotechnologies Inc. news in 2025

Frontier Biotechnologies Inc.'s news releases, calls and decks from 2025, newest first.

View company

Announcement on Resolutions of the 9th Meeting of the 4th Board of Directors

December 11, 2025

Announcement on Election of Employee Directors for the 4th Board of Directors

November 19, 2025

Announcement on Convening the Q3 2025 Performance Briefing

October 30, 2025

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

October 9, 2025

Publicity Description and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on the List of Incentive Objects Initially Granted in the 2025 Restricted Stock Incentive Plan

September 29, 2025

Announcement on Resolutions of the 6th Meeting of the 4th Board of Supervisors

September 17, 2025

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

September 16, 2025

Announcement on Repayment of Previously Temporarily Used Raised Funds for Working Capital and Continued Use of Partial Idle Raised Funds to Temporarily Supplement Working Capital

September 11, 2025

Announcement on Changing Some Investment Projects Financed by Raised Funds

August 29, 2025

Announcement on Resolutions of the 3rd Meeting of the 4th Board of Supervisors

July 18, 2025

Announcement on Reply to the Regulatory Inquiry Letter on Information Disclosure of 2024 Annual Report

June 20, 2025

Announcement on Change of Sponsor Representative

May 26, 2025

Announcement on Resolution of the 2024 Annual General Meeting

May 23, 2025

Announcement on Signing the Supplementary Agreement and Passive Extension of Related Party Loans

April 29, 2025

Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Companies on SSE STAR Market 2024 and Convening the Q1 2025 Performance Briefing

April 27, 2025

Announcement on Preliminary Earnings Estimate for 2024

February 27, 2025

Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in China

January 20, 2025

Voluntary Disclosure Announcement on Approval of Phase II Clinical Trial for New Indication of Immune Reconstitution Insufficient of Aikening

January 17, 2025